A patient suffering from a degenerative cardiac condition is undergoing experimental therapy. Scientists choose to reprogram the patient's own mature somatic cells into induced pluripotent stem cells (iPSCs) rather than sourcing human embryonic stem cells (hESCs) from an IVF clinic.
Describe three distinct advantages of using these patient-derived iPSCs in medical treatments and research compared to using embryonic stem cells.
